Effect of Itopride, on Symptoms of Functional Dyspepsia, Such as Indigestion, Bloating, Inability to Finish a Meal
NCT00112177 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 500
Last updated 2017-02-08
Summary
Itopride is a new compound that is already marketed in Japan and in some countries of Eastern Europe under the name of Ganaton. It is used to treat symptoms of functional dyspepsia. Patients suffering from this condition have difficulties digesting food. They feel full after eating a few bites; they feel bloated and their stomachs hurt. The goal of this study is to see if itopride helps to relieve the symptoms of functional dyspepsia.
Conditions
- Dyspepsia
Interventions
- DRUG
-
Itopride Hydrochloride
Sponsors & Collaborators
-
Forest Laboratories
lead INDUSTRY
Principal Investigators
-
Jan Tack, Professor · Universitaire Ziekenhuizen KU Leuven
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-07-31
- Primary Completion
- 2006-08-31
- Completion
- 2006-08-31
Countries
- Canada
Study Locations
More Related Trials
-
Psychological and Dietary Treatment in IBS
NCT04770883 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
IQP-CL-101 in IBS Management
NCT01774825 ·Status: COMPLETED ·Phase: PHASE3
-
Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders
NCT02566876 ·Status: COMPLETED ·Phase: PHASE4
-
Clinical Improvement and in Quality of Life-Functional Dyspepsia-
NCT01802710 ·Status: COMPLETED ·Phase: NA
-
Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating
NCT02299973 ·Status: COMPLETED ·Phase: NA
-
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
NCT00067561 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Safety of "BST104" (Lonicera Flos Extract) in Mild to Moderate Functional Dyspepsia Subjects
NCT04008901 ·Status: COMPLETED ·Phase: PHASE3
-
Tritordeum-based Foods for IBS Symptoms
NCT05307185 ·Status: COMPLETED ·Phase: NA
-
Treatment of Constipation in Functional Dyspepsia
NCT02956187 ·Status: COMPLETED ·Phase: NA
-
Genetic Carbohydrate Maldigestion As Model to Study Food Hypersensitivity Mechanism (WORK PACKAGE 2)
NCT06770907 ·Status: NOT_YET_RECRUITING
-
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
NCT04656730 ·Status: COMPLETED ·Phase: PHASE4
-
Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia
NCT00956397 ·Status: COMPLETED ·Phase: NA
-
Gabapral in Pediatric IBS
NCT05737277 ·Status: UNKNOWN ·Phase: NA
-
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
NCT00394173 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Carbohydrates in Irritable Bowel Syndrome
NCT04830410 ·Status: COMPLETED ·Phase: NA
-
Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid
NCT01449487 ·Status: COMPLETED ·Phase: PHASE1
-
Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
NCT00067457 ·Status: COMPLETED ·Phase: PHASE3
-
Fengliao Changweikang for Diarrhea-predominant Irritable Bowel Syndrome: N-of-1 Trial
NCT07061184 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Traditional Dietary Advice Versus Low FODMAP Diet in Postprandial Functional Dyspepsia
NCT05810168 ·Status: COMPLETED ·Phase: NA
-
A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT01844180 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Learn More About the Stomach and Intestine Complaints of Children Aged From 3 to 14 Years
NCT04029376 ·Status: COMPLETED
-
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c
NCT00215566 ·Status: COMPLETED ·Phase: PHASE2
-
A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome
NCT02970591 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Open Label Placebo in Children With FGIDs
NCT02389998 ·Status: COMPLETED ·Phase: NA
-
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
NCT01553747 ·Status: COMPLETED ·Phase: PHASE3